Richard Lehman’s journal review—20 July 2015

NEJM 16 July 2015 Vol 373 209 I’ll say it again: “Cancer boasts the worst trials in medicine. Also the worst drug regulation. Also the worst cost/benefit ratio for new treatments. And also the worst drug toxicities. Plus the highest levels of public and charitable funding. My forehead hits the desk when I read about […]

Read More…

Richard Lehman’s journal review—13 July 2015

NEJM 9 July 2015 Vol 373 111 First they defined a new disease category. Then they promoted a mechanistic explanation. Then they made everyone focus on the pathway that matched the latest drugs. Then they made billions of dollars selling the drugs. By the time the whole edifice started to look shaky, everybody was complicit […]

Read More…

Richard Lehman’s journal review—29 June 2015

NEJM 25 June 2015  Vol 372 2533  The research articles in this week’s print NEJM are all about arcane stuff I’ve covered previously. The Clinical Practice article takes us back to the real world—the one we’d rather not think about, where there is a smell of urine and random cries from rooms down the corridor. […]

Read More…

Richard Lehman’s journal review—15 June 2015

NEJM 11 June 2015 Vol 372 2307 Here at last is a study that shows some benefit from out of hospital cardiopulmonary resuscitation. It’s not a randomised trial, since that would be considered unethical, or at least heretical. Instead it comes from interrogating a big Swedish database of outcomes following cardiac arrests outside hospitals. “CPR […]

Read More…

Richard Lehman’s journal review—8 June 2015

NEJM 4 Jun 2015 Vol 372 2185 If you are the sort of exciting doctor who looks after adults with acute hypoxaemic respiratory failure, here is just the article you need. It’s a French trial comparing the effect of high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation. The […]

Read More…